中文版正在生成中，先为你展示英文版分析。
AI核心结论
HCA Healthcare delivered strong FY2025 results with revenue rising 7.1% to $75.6B and net income surging 17.8% to $6.8B, driven by robust operating cash flow of $12.6B, even as aggressive share buybacks of $10.1B deepened the company's negative stockholders' equity position.
营业收入
$75.6B
同比 ++7.08%
每股收益（基本）
$28.70
同比 ++28.87%
提交于 · 解读更新于 · 来源: SEC EDGAR 10-K 原文
HCA Healthcare (HCA) FY2025 营收 $75.6B，同比增长 7.1%。 净利润 $6.78B，同比增长 17.8%，稀释每股收益 $28.33。
HCA grew total revenue by 7.1% year-over-year from $70.6B to $75.6B in FY2025, reflecting continued strong patient volumes and favorable reimbursement trends across its hospital and outpatient network.
来源: Source: 10-K Income Statement (XBRL Financial Data)
Net income increased 17.8% to $6.8B, while diluted EPS jumped 28.8% from $22.00 to $28.33, with the outsized EPS growth relative to net income growth reflecting the significant reduction in share count from $10.1B in buybacks during FY2025.
来源: Source: 10-K Income Statement & Cash Flow Statement (XBRL Financial Data)
Operating cash flow rose 20.2% to $12.6B in FY2025 from $10.5B in the prior year, demonstrating HCA's ability to convert earnings into cash efficiently, with D&A of $3.5B supporting free cash flow generation.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
HCA returned substantial capital to shareholders through $10.1B in share repurchases (up 66.6% YoY) and $679M in dividends, totaling approximately $10.7B in FY2025, funded primarily by strong operating cash flows and incremental debt.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
Long-term debt increased modestly to $44.3B while stockholders' equity deteriorated sharply to -$6.0B from -$2.5B, driven by the aggressive buyback program exceeding retained earnings, a structural feature common to highly leveraged capital return strategies.
来源: Source: 10-K Balance Sheet (XBRL Financial Data)
HCA carries $44.3B in long-term debt and a stockholders' equity deficit of -$6.0B as of FY2025, a deterioration of 141.2% from the prior year. This leverage concentration increases vulnerability to interest rate changes and limits financial flexibility in a downturn.
来源: Source: 10-K Balance Sheet (XBRL Financial Data)
HCA's current ratio stands at approximately 0.97, meaning current liabilities of $16.4B exceed current assets of $15.8B. Combined with a 46.2% decline in cash and equivalents to just $1.0B, near-term liquidity could be strained if operating conditions deteriorate.
来源: Source: 10-K Balance Sheet (XBRL Financial Data)
HCA spent $10.1B on share repurchases in FY2025, a 66.6% increase over the prior year, which significantly exceeds its net income of $6.8B. Continued buybacks at this pace would require additional debt issuance or a reduction in capital expenditures, potentially constraining future growth investments.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
Investing cash outflows of approximately $5.0B in FY2025 reflect the capital-intensive nature of hospital operations and ongoing facility investments. Any reduction in reinvestment could impair HCA's competitive positioning and regulatory compliance over time.
来源: Source: 10-K Cash Flow Statement (XBRL Financial Data)
HCA's revenue growth is closely tied to Medicare, Medicaid, and commercial insurance reimbursement rates. Any adverse changes in government reimbursement policy or a shift toward lower-paying payers could materially impact revenue and margins without a corresponding reduction in costs.
来源: Source: 10-K Income Statement (XBRL Financial Data)
FY2025 实际 EPS $8.14，分析师一致预期 $7.53，超预期 +8.0%。
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业收入 | $75.6B | $70.6B | +7.08% |
净利润 | $6.78B | $5.76B | +17.78% |
每股收益（基本） | $28.70 | $22.27 | +28.87% |
每股收益（稀释） | $28.33 | $22.00 | +28.77% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
总资产 | $60.72B | $59.51B | +2.03% |
流动资产 | $15.78B | $16.41B | -3.84% |
流动负债 | $16.35B | $15.18B | +7.73% |
股东权益 | $-6.03B | $-2.5B | -141.18% |
现金及等价物 | $1.04B | $1.93B | -46.20% |
长期债务 | $44.28B | $43.03B | +2.91% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
经营活动现金流 | $12.64B | $10.51B | +20.18% |
投资活动现金流 | $-4.99B | $-4.93B | -1.11% |
筹资活动现金流 | $-8.55B | $-4.58B | -86.60% |
股息支出 | $679M | $690M | -1.59% |
股票回购 | $10.07B | $6.04B | +66.62% |
折旧及摊销 | $3.52B | $3.31B | +6.37% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
净利率 | 9.0% | — | — |
净资产收益率 | -112.6% | — | — |
总资产收益率 | 11.2% | — | — |
流动比率 | $0.965 | — | — |
Health Care Facilities 行业其他公司
HCA had a strong FY2025, with revenue growing 7.1% to $75.6B and net income rising 17.8% to $6.8B. Diluted EPS jumped 28.8% to $28.33, partly boosted by $10.1B in share repurchases that reduced the share count significantly.
HCA's diluted EPS grew 28.8% while net income grew 17.8% because the company repurchased $10.1B worth of its own shares in FY2025, a 66.6% increase over the prior year. Fewer shares outstanding means each remaining share represents a larger portion of earnings, amplifying EPS growth beyond net income growth.
HCA's negative stockholders' equity of -$6.0B is primarily a result of its aggressive share buyback program, not operating losses — the company generated $6.8B in net income and $12.6B in operating cash flow in FY2025. However, the combination of $44.3B in long-term debt and a current ratio below 1.0 means investors should monitor leverage levels closely.
HCA returned approximately $10.7B to shareholders in FY2025, consisting of $10.1B in share repurchases (up 66.6% year-over-year) and $679M in dividends. This capital return program was funded by the company's strong operating cash flow of $12.6B.
The most significant risks include HCA's high leverage with $44.3B in long-term debt and negative equity of -$6.0B, a current ratio below 1.0 indicating near-term liquidity tightness, and dependence on government and commercial reimbursement rates for the majority of its revenue. The pace of share buybacks, which exceeded net income in FY2025, also raises questions about long-term balance sheet sustainability.